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Serotonin enhances the production of type IV collagen by human
mesangial cells.
Background. The plasma concentration of 5-hydroxytryptamine
(5-HT) in diabetic patients is higher than that in normal subjects.
Since recent reports have demonstrated the presence of 5-HT2A
receptor in glomerular mesangial cells, it is possible that 5-HT
may be involved in the development of diabetic nephropathy
through the 5-HT2A receptor in mesangial cells. Because expan-
sion of the glomerular mesangial lesion is a characteristic feature
of diabetic nephropathy, we examined the effect of 5-HT on the
production of type IV collagen by human mesangial cells.
Methods. Human mesangial cells were incubated with 5-HT
with or without 5-HT receptor antagonists, protein kinase C
(PKC) inhibitor or transforming growth factor-b (TGF-b) anti-
body. Type IV collagen mRNA and protein concentration in
medium were measured by Northern blot analysis and enzyme-
linked immunosorbent assay (ELISA), respectively. TGF-b
mRNA and bioactivity in the medium were measured by Northern
blot analysis and bioassay using mink lung epithelial cells, respec-
tively.
Results. 5-HT stimulated the production of type IV collagen by
human mesangial cells, which was inhibited by ketanserin and
sarpogrelate hydrochloride, 5-HT2A receptor antagonists, but not
by ondansetron, a 5-HT3 receptor antagonist. 5-HT increased the
bioactivities of both active and total TGF-b. However, the 5-HT-
enhanced production of type IV collagen was completely inhibited
by an anti-TGF-b antibody. Furthermore, a PKC inhibitor, cal-
phostin C, inhibited the 5-HT-induced increase in type IV colla-
gen secretion, and the activity of membrane PKC was increased by
5-HT. Phorbol ester activated type IV collagen production as well
as active and total TGF-b. Calphostin C completely inhibited the
5-HT-enhanced activity of active TGF-b, but did not inhibit
exogenous TGF-b-induced increase in type IV collagen secretion.
Conclusions. Our results suggest that 5-HT-enhanced produc-
tion of type IV collagen by human mesangial cells is mediated by
activation of PKC and subsequent increase in active TGF-b
activity.
Serotonin [5-hydroxytryptamine (5-HT)], a decarboxyl-
ation derivative of the amino acid tryptophan, is an active
molecule released mainly from activated platelets [1]. Re-
cent reports have emphasized that the proximal renal
tubules also produced a significant amount of 5-HT that
may modulate renal phosphorus transport in a paracrine
fashion [2]. 5-HT is also known to have several biological
activities, for example, it acts as a neurotransmitter in the
central and sympathetic nervous systems, a potent constric-
tor of smooth muscle cells, and an activator of platelets [3].
The plasma concentration of 5-HT is particularly high in
diabetic patients [4, 5], suggesting that it may be involved in
the development of diabetic complications (through arte-
rial contraction and platelet aggregation), although there is
no clear clinical evidence for its involvement in the patho-
genesis of diabetic nephropathy. However, a recent study
by Nebigil et al showed the presence of 5-HT2A receptor
subtype on glomerular mesangial cells [6], suggesting that a
direct effect of 5-HT on mesangial cells through its recep-
tor might be involved in the development of diabetic
nephropathy.
Expansion of the glomerular mesangial lesion is one of
the histological features of diabetic nephropathy [7]. The
mesangial matrix is normally composed of various macro-
molecules, including fibronectin, laminin, and collagen [8,
9]. Among these molecules, the metabolism of type IV
collagen has been extensively examined in diabetic mesan-
gial lesions. Mesangial cells are thought to play an impor-
tant role in the metabolism of type IV collagen by modu-
lating its synthesis and degradation [8, 9]. In vitro
experiments using rat mesangial cells have shown that high
glucose concentrations [10] and exogenous transforming
growth factor- b (TGF-b) [11, 12] induce the secretion of
type IV collagen. However, the mechanism of accumula-
tion of type IV collagen in diabetic mesangial lesions
remains to be elucidated.
In the present study, we examined the effect of 5-HT on
the production of type IV collagen by human mesangial
cells, and demonstrated that 5-HT stimulated type IV
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collagen secretion from human mesangial cells by activa-
tion of protein kinase C (PKC) with subsequent increase in
active TGF-b.
METHODS
Chemicals
Serotonin (5-hydroxytryptamine hydrochloride crystal-
line), ketanserin (5-HT2A receptor antagonist), and cal-
phostin C (a PKC inhibitor) were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Calphostin C was
dissolved in dimethyl sulfoxide (DMSO). The final concen-
tration of DMSO was less than 0.1% in the culture medium
which did not affect viability and growth of mesangial cells.
Sarpogrelate hydrochloride (5-HT2A receptor antagonist)
was a generous gift from Tokyo Tanabe Co., Ltd. (Tokyo,
Japan). Ondansetron (5-HT3 receptor antagonist) was a
generous gift from Sankyo Co., Ltd. (Tokyo, Japan). All
other chemicals were of the best grade available from
commercial sources.
Cells
The experimental protocol was approved by the Human
Ethics Review Committee of our institution and a signed
consent form was obtained from each patient. Human
glomeruli were isolated according to the method of Gro¨ne
et al [13], with minor modifications [14, 15]. Briefly, the
kidneys of patients with ureteral cancer were removed and
the cortices of normal sections were cut and pressed
through a series of sieves of decreasing pore size (250, 125
and 110 mm). After passing through the finest sieve, the
collected tissue was rinsed twice with Hank’s balanced salt
solution (HBSS; Nissui Pharmaceutical Co., Tokyo, Japan)
and centrifuged (3,000 3 g) for 10 minutes. The pellet was
resuspended in 5 ml of HBSS containing 750 U/ml colla-
genase (Sigma) and incubated for 30 minutes at 37°C. After
incubation, digested glomeruli were washed five times with
phosphate buffered saline (PBS) and the glomerular cores
were cultured at 37°C in RPMI 1640 (Life Technologies,
Inc., Grand Island, NY, USA) with 20% fetal calf serum
(FCS), 100 U/ml penicillin, 10 mg/ml streptomycin, 250
mg/ml amphotericin B and ITSy premix (Becton Dickinson,
Bedford, MA, USA) in 75 cm2 plastic tissue culture flasks
in a 5% CO2 incubator. Cultured human mesangial cells
between the fifth and eighth passages formed a uniform cell
population as evaluated by the following criteria: (1) spin-
dle shape, (2) positive immunohistochemistry with antibody
for a-actin and vimentin, and negative for cytokeratin and
Factor VIII, and (3) contraction in response to angiotensin
II. Mesangial cells (5 3 104 cells/well) were plated onto
12-well plates and incubated in RPMI 1640 with 20% FCS,
100 U/ml penicillin, 10 mg/ml streptomycin, 250 mg/ml
amphotericin B for 24 hours. Then, cells were incubated
with 5-HT for 24 hours, 48 hours or 72 hours for determi-
nation of type IV collagen secretion and TGF-b bioactivity.
5-HT is known to induce mesangial cell growth [16]. In a
series of preliminary studies, mesangial cell growth was
induced by 5-HT as confirmed by using [3H] thymidine
incorporation and cell counting assays. Thus, the data of
type IV collagen secretion and TGF-b bioactivity were
expressed on a cellular protein basis.
Enzyme-linked immunosorbent assay of type IV collagen
Type IV collagen was measured by enzyme-linked immu-
nosorbent assay described by Rennard et al [17] with minor
modifications. In brief, 50 ml type IV collagen standards or
conditioned media from mesangial cells were incubated
with 50 ml of anti-type IV collagen IgG diluted with PBS
containing 0.5% bovine serum albumin at 4°C for 16 hours.
In the next step, 90 ml of the reaction mixture was
transferred to the well of 96 multi-well plate (Falcon;
Becton Dickinson and Co., Lincoln Park, NJ, USA) pre-
coated with type IV collagen (1 mg type IV collagen/well in
0.02 mol/liter carbonate buffer, pH 9.6 at 4°C overnight)
and the plate was incubated at 37°C for 60 minutes. After
rinsing each well three times with a washing buffer (PBS
with 0.1% Tween 20), 100 ml anti-rabbit IgG conjugated
with peroxidase (Tago, Inc., Burlingame, CA, USA) was
added to the well, incubated at 37°C for 60 minutes and
rinsed three times. The final reaction mixture (0.04 mg/dl
o-phenylenediamine dihydrochloride and 0.06% H2O2 0.05
mol/liter citrate buffer, pH 5.0) was then added and
incubated at room temperature for two minutes. The
reaction was stopped by adding 50 ml H2SO4 followed by
measurement of absorbance at 490 nm.
TGF-b bioassay
The assay used in the present experiments was essentially
similar to that described previously by Ikeda, Lioubin and
Marquardt [18]. An aliquot of the medium was used to
determine the active form of TGF-b by the bioassay
described below. To determine the total TGF-b in the
medium, the remaining portion was acidified to pH 2 with
1 mol/liter HCl for 30 minutes at room temperature,
dialyzed for 24 hours at 4°C against RPMI 1640 and
subjected to the bioassay described below.
Mvl Lu mink lung epithelial cells (CCL-64) were pur-
chased from American Type Culture Collection and cul-
tured in RPMI 1640 with 10% FCS, 100 U/ml penicillin and
0.1 mg/ml streptomycin (medium A). Before the bioassay,
cells were subcultured for two hours at 3.5 3 103 cells/well
in a 96-well tissue culture plate in 50 ml of medium A. In
the next step, 50 ml of the conditioned medium to be tested
was added to each well and incubated for four days at 37°C.
During the last 24 hours of incubation, cells in each well
were chased with 10 ml of 10 mCi/ml [3H] thymidine, and
the radioactivity incorporated into the cells was counted in
a liquid scintillation spectrophotometer. For each assay, a
standard curve for TGF-b was constructed by 0.01 to 5
ng/ml of a recombinant human TGF-b [18] with or without
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5-HT. [3H] thymidine incorporation into CCL-64 cells was
not affected by 5 3 1025 mol/liter of 5-HT (data not
shown), demonstrating that 5-HT in the conditioned me-
dium of mesangial cells did not alter TGF-b bioactivity.
Under these assay conditions, the addition of 10 mg/ml of a
mouse anti-human TGF-b antibody (Genzyme, Cam-
bridge, MA, USA) [19] could neutralize . 95% of the
TGF-b-induced growth inhibition of CCL-64 cells.
Assay of protein kinase C activity
PKC activity in human mesangial cells was assayed by
MESACUP Protein Kinase Assay Kit (Medical and Bio-
logical Laboratories, Nagoya, Japan). Human mesangial
cells (1 3 107 cells/well) in 2 ml of serum-free RPMI 1640
medium were treated with 1026 mol/liter of 5-HT for
indicated time intervals. The cells were washed three times
in ice-cold PBS and detached from the plates with rubber
policeman. Cells were suspended in 1 ml of sample prepa-
ration buffer (in mmol/liter, 5 EDTA, 10 EGTA, 50
2-mercaptoethanol, 1 PMSF, 10 benzamidine and 50 Tris-
HCl, pH 7.5), and sonicated for 30 seconds at 4°C by
Sonifier (Branson Sonic Power Co., USA). Homogenates
were centrifuged at 100,000 3 g for one hour at 4°C. The
supernatant was discarded and the precipitates were resus-
pended in 1 ml of preparation buffer and used as the
membrane fractions. PKC activity in the membrane frac-
tions was measured as follows. Twelve microliters of mem-
brane fractions (5 mg) were added to 108 ml of component
buffer (final concentration of reaction mixture was 3 mmol/
liter MgCl2, 0.1 mmol/liter ATP, 2 mmol/liter CaCl2, 50
mg/ml phosphatidylserine, 0.5 mmol/liter EDTA, 1 mmol/
liter EGTA, 5 mmol/liter 2-mercaptoethanol and 25 mmol/
liter Tris-HCl, pH 7.0). In the next step, 100 ml of this
mixture was transferred to each well coated with PKC-
specific peptide (RFARKGSLRQKNV) using a multichan-
nel pipette. Each well was incubated at 25°C for five
minutes and the reaction was terminated by the addition of
100 ml of 20% H3PO4, followed by washing five times with
200 ml of PBS. To each well we added 100 ml of biotinylated
anti-phosphorylated serine antibody (2B9) and the mixture
was incubated at 25°C for 60 minutes, and washed five
times with PBS. The mixture was further incubated at 25°C
for 60 minutes after the addition of 100 ml of peroxidase
conjugated streptavidin to each well, followed by washing
five times with PBS. After the addition of 100 ml of H2O2
and o-phenylenediamine, the mixture was incubated at
25°C for five minutes, followed by the addition of 100 ml of
20% H3PO4. Finally, the absorbance was read at 492 nm
with a microplate reader. Nonspecific serine/threonine-
kinase activities were measured both in the absence of
phosphatidyl serine and in the presence of 2 mmol/liter
EGTA in component buffer. The enzyme activity in the
membrane fraction specific for conventional PKC was
quantitated by subtracting the nonspecific serine/threo-
nine-kinase activities from total kinase activity.
Northern blot analysis
The cDNA probes used were a 0.8 kb EcoRI fragment
encoding human a1(IV) collagen and a 0.6 kb SmaI
fragment encoding human TGF-b. Each mRNA was iso-
lated from human mesangial cells using QuickPrep (Phar-
macia, Uppsala, Sweden). For Northern blot analysis, 0.4
mg of mRNA from each sample of human mesangial cells
was electrophoresed in 1% agarose gel and transferred to
nitrocellulose filter (Nitroplus 2000; Micro Separations,
Westboro, MA, USA) for 18 hours at room temperature
using 10 3 SSC as the transfer solution and cross-linked by
UV (FS 1500, Funakoshi, Japan) at 12 J/cm2. Prehybrid-
ization with salmon sperm DNA was performed for three
hours followed by hybridization for eight hours using 50%
formamide with a 32P-radiolabeled probes (Multiprine;
Amersham, Arlington Height, IL, USA). Hybridized filters
were washed with 1 3 SSC (0.1% SDS) for 15 minutes, and
twice with 0.1 3 SSC (0.1% SDS) for 15 minutes at 60°C.
The filters were then exposed to Kodak XAR-5 film using
an intensifying screen for two days at 280°C.
Statistical analysis
Data were expressed as mean 6 SD. Differences between
groups were evaluated by paired Student’s t-test. A P value
less than 5% denoted the presence of a statistically signif-
icant difference.
RESULTS
Effect of 5-HT on production of type IV collagen by
human mesangial cells
We first examined the in vitro effect of 5-HT on the
production of type IV collagen by human mesangial cells.
When mesangial cells were incubated with the medium
alone for 24 hours, the baseline concentration of type IV
collagen was 15 mg/mg cell protein, indicating that type IV
collagen was constitutively produced by human mesangial
cells (Fig. 1A). Incubation of mesangial cells with various
concentrations of 5-HT for 24 hours significantly increased
the production of type IV collagen in a dose-dependent
manner, and the peak concentration was observed at 1026
mol/liter of 5-HT (Fig. 1A). We also examined the kinetics
of type IV collagen secretion in the presence or absence of
5-HT. In the control media, the concentration of type IV
collagen increased in a time-dependent manner, but its
production by mesangial cells was significantly higher,
relative to controls, at each time interval when these cells
were incubated in the presence of 1026 mol/liter of 5-HT
(Fig. 1B). When human mesangial cells were incubated
with 1026 mol/liter of 5-HT together with various concen-
trations of ketanserin or sarpogrelate hydrochloride,
5-HT2A receptor antagonists, 5-HT-induced increase in
type IV collagen secretion was completely suppressed by
these agents (Fig. 1C). In contrast, the 5-HT3 receptor
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antagonist, ondansetron, did not affect 5-HT-induced in-
crease in type IV collagen production (Fig. 1C). These
results suggested that the 5-HT-enhanced production of
type IV collagen might be mediated through the 5-HT2A
receptor.
Northern blot analysis of type IV collagen a1 showed
that 5-HT increased the mRNA level of type IV collagen
a1 chain in a time-dependent manner and a significant
difference was observed at 24 hours following the addition
of 1026 mol/liter of 5-HT (Fig. 2). Figure 3 shows that both
constitutive and 5-HT-induced type IV collagen production
were completely inhibited by cycloheximide (Fig. 3). These
results suggested that 5-HT-enhanced production of type
IV collagen is regulated at a transcriptional level.
Fig. 2. Effect of 5-HT on mRNA of type IV collagen a1 chain by human
mesangial cells. Human mesangial cells were incubated with 1026 mol/
liter of 5-HT for indicated time. The mRNA was isolated and 0.4 mg of
mRNA were separated by electrophoresis in formaldehyde-containing gel
and transferred to a nitrocellulose filter. The filter was hybridized with a
heat-denatured 32P-labeled a1(IV) probe. As a control, 18S and 28S were
visualized on a UV monitor.
Fig. 3. Effect of cycloheximide on production of type IV collagen by
human mesangial cells. Human mesangial cells (5 3 104 cells/well) were
incubated with (F) or without (f) 1026 mol/liter of 5-HT in the absence
or the presence of indicated concentrations of cycloheximide. After 24
hours of incubation, the concentration of type IV collagen in the medium
was determined. Data represent the mean 6 SD of three separate
experiments. *P , 0.05, compared with cells incubated with 1026mol/liter
of 5-HT without cycloheximide.
Fig. 1. Effects of 5-hydroxytryptamine (5-HT) and 5-HT receptor antagonists on production of type IV collagen by human mesangial cells. (A) Human
mesangial cells (5 3 104 cells/well) were incubated with the indicated concentrations of 5-HT. After 24 hours incubation, type IV collagen concentrations
in the medium were determined. Data represent the mean of three separate experiments. Error bars indicate SDs. *P , 0.05, compared with control.
(B) Human mesangial cells (5 3 104 cells/well) were incubated in the absence (M) or the presence (f) of 1026 mol/liter of 5-HT for 24, 48, and 72 hours.
After incubation, the concentration of type IV collagen in the medium was determined. Data represent the mean 6 SD of three separate experiments.
(C) Human mesangial cells (5 3 104 cells/well) were incubated with 1026 mol/liter of 5-HT in the absence or presence of indicated concentrations of
ketanserin (E), ondansetron (l), and sarpogrelate hydrochloride (F). As a control, human mesangial cells were incubated with medium alone (M).
After 24 hours incubation, the concentration of type IV collagen in the medium was determined. Data represent the mean 6 SD of three separate
experiments. *P , 0.05, compared with cells incubated with 1026mol/liter of 5-HT alone.
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Involvement of TGF-b in 5-HT-induced increase in type
IV collagen production
To elucidate the mechanism of 5-HT-enhanced produc-
tion of type IV collagen, we examined the involvement of
TGF-b in this process in the next series of experiments.
Bioactivities of both active and total TGF-b significantly
increased following the addition of 5-HT in a dose-depen-
dent manner, and the peak activity of active and total
TGF-b occurred in the presence of 1026 mol/liter of 5-HT
(Fig. 4A). Interestingly, 5-HT-stimulated bioactivity of ac-
tive TGF-b (Fig. 4A) paralleled the rise in type IV collagen
secretion (Fig. 1A). The time course study of TGF-b
bioactivity showed that both active and total TGF-b activ-
ities became significant at 12 hours after the addition of
5-HT (Fig. 4B). Figure 4C shows that the level of TGF-b
mRNA was increased by 5-HT. These results demonstrated
that 5-HT increased both total and active TGF-b bioactiv-
ities. Figure 5A shows that non-immune IgG failed to
change the effect of 5-HT on type IV collagen production,
whereas an anti-TGF-b antibody significantly inhibited
5-HT-induced type IV collagen production. Moreover,
anti-TGF-b antibody partially suppressed the constitutive
secretion of type IV collagen. The level of anti-TGF-b
antibody-induced suppression of type IV collagen produc-
tion was less than the constitutively produced type IV
collagen, suggesting the potential involvement of TGF-b in
5-HT-enhanced production of type IV collagen, as well as,
at least in part, in constitutive secretion. To test this
conclusion, we determined the effect of exogenous active
TGF-b on the production of type IV collagen in the culture
medium. Figure 5B shows that the addition of exogenous
active TGF-b to these cells markedly increased type IV
collagen secretion in a dose-dependent manner (up to 100
pmol/liter). Combined together, these results indicate that
TGF-b may play an important role in 5-HT-enhanced
production of type IV collagen.
Fig. 4. Effects of 5-HT on total and active TGF-b bioactivities and TGF-b mRNA expression. (A) Human mesangial cells (5 3 104 cells/well) were
incubated with the indicated concentrations of 5-HT. After 24 hours incubation, total (upper panel) and active (lower panel) TGF-b bioactivities in the
medium were determined. Data represent the mean 6 SD of three separate experiments. *P , 0.05, compared with the control. (B) Human mesangial
cells (5 3 104 cells/well) were incubated in the absence (M) or the presence (f) of 1026 mol/liter of 5-HT for indicated times. Total (upper panel) and
active (lower panel) TGF-b bioactivities in the medium were determined. Data represent the mean 6 SD of three separate experiments. (C) Northern
blot analysis of TGF-b. Human mesangial cells were incubated with 1026 mol/liter of 5-HT. The mRNA of these cells was harvested at 0, 12, 24 hours.
The mRNA (0.4 mg) was separated by electrophoresis in for aldehyde-containing gel and transferred to a nitrocellulose filter. The filter was hybridized
with a heat-denatured 32P-labeled TGF-b probe. As a control, 18S and 28S were visualized on a UV monitor.
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Involvement of protein kinase C in 5-HT-enhanced
production of type IV collagen
Figure 6A shows the time course study of membrane
PKC activity. The addition of 1026 mol/liter of 5-HT to
human mesangial cells resulted in 2.5-fold rise in enzyme
activity (relative to basal level) at five minutes and in
7.0-fold increase above the basal level at 10 minutes.
However, this was followed by a rapid decline to levels
close to the baseline at 20 minutes (Fig. 6A). To elucidate
the role of PKC on 5-HT-enhanced production of type IV
collagen, we examined the effect of a PKC inhibitor,
calphostin C, on this process. Incubation of human mesan-
gial cells with 1026 mol/liter of 5-HT together with various
concentrations of calphostin C suppressed 5-HT-induced
increase in type IV collagen secretion in a dose-dependent
manner, with 50% inhibition at 50 nmol/liter of calphostin
C and a maximal inhibition at 100 nmol/liter (Fig. 6B).
Interestingly, calphostin C did not affect the constitutive
production of type IV collagen in human mesangial cells
(Fig. 6B). Under the experimental conditions described
above, calphostin C was not cytotoxic to human mesangial
cells. This conclusion was based on results of the cell
counting assay using trypan blue staining and the release of
lactic dehydrogenase from these cells (data not shown).
These results suggest that PKC may be involved in the
production of type IV collagen. To confirm the involvement
of PKC in type IV collagen production, we examined the
effect of phorbol ester, a well known PKC activator, on type
IV collagen production and TGF-b activity. Figure 7A
shows that phorbol ester induced an increase in type IV
collagen production as well as activation of active and total
TGF- b (Fig. 7B). These results suggested that 5-HT-
induced type IV collagen production was mediated by
activation of PKC, which in turn increased TGF-b activity
in human mesangial cells. To test this notion, we examined
the effect of calphostin C on 5-HT-stimulated TGF-b
Fig. 5. Inhibitory effect of anti-TGF-b antibody
and effect of exogenous TGF-b on type IV
collagen production. (A) Human mesangial cells
(5 3 104 cells/well) were incubated with (E,F) or
without (M,f) 1026 mol/liter of 5-HT in the
absence or presence of indicated concentrations
of anti-TGF-b antibody (F,f) or non-immune
IgG (E,M). After 24 hours incubation, the
concentration of type IV collagen in the medium
was determined. Data represent the mean 6 SD
of three separate experiments. *P , 0.05,
compared with non-immune IgG. (B) Human
mesangial cells (5 3 104 cells/well) were
incubated with the indicated concentrations of
exogenous TGF-b. After 24 hours incubation, the
concentration of type IV collagen in the medium
was determined. Data represent the mean 6 SD
of three separate experiments. *P , 0.05,
compared with the control.
Fig. 6. Involvement of protein kinase C (PKC)
in 5-HT-induced production of type IV collagen.
(A) Human mesangial cells (1 3 107 cells) were
incubated with 1026 mol/liter of 5-HT for the
indicated time interval. The activity of
membrane PKC was determined. Data
represent the mean 6 SD of three separate
experiments. *P , 0.05, compared with baseline
(0 min). (B) Human mesangial cells (5 3 104
cells/well) were incubated with (F) or without
(f) 1026 mol/liter of 5-HT in the absence or
presence of the indicated concentrations of
calphostin C. As control, the cells were
incubated with 0.1% DMSO in the presence
(E), or absence (M) of 1026 mol/liter 5-HT.
After 24 hours of incubation, the concentration
of type IV collagen in the medium was
determined. Data represent the mean 6 SD of
three separate experiments. *P , 0.05,
compared with cells incubated with 1026 mol/
liter of 5-HT without calphostin C.
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bioactivity. A complete inhibition of 5-HT-induced in-
crease in active and total TGF-b bioactivities was noted
following the addition of 100 nmol/liter of calphostin C
(Fig. 8). Moreover, the effect of exogenous TGF-b on the
concentration of type IV collagen was not inhibited by
calphostin C (data not shown). Thus, our results suggest
that 5-HT-induced production of type IV collagen by
human mesangial cells is mediated by activation of PKC
and the subsequent increase in active TGF-b activity.
DISCUSSION
The major findings of the present study were that 5-HT
enhanced the production of type IV collagen by human
mesangial cells in the kidney, and that this effect was
mediated by activation of PKC with a subsequent increase
in active TGF-b bioactivity. These conclusions were sup-
ported by the following findings: (1) production of type IV
collagen by human mesangial cells increased following the
addition of 5-HT to the medium (Fig. 1 A, B), which was
inhibited by 5-HT2A receptor antagonists (Fig. 1C); (2) the
bioactivities of both active and total TGF-b were increased
by 5-HT (Fig. 4); (3) 5-HT-enhanced production of type IV
collagen was completely inhibited by an anti-TGF-b anti-
body (Fig. 5A); (4) the activity of membrane PKC was
increased by 5-HT (Fig. 6A); (5) inhibition of PKC by
calphostin C suppressed the stimulatory effect of 5-HT on
type IV collagen production (Fig. 6B); (6) phorbol ester
enhanced activation of active TGF-b and production of
type IV collagen (Fig. 7); (7) increased bioactivity of
TGF-b by 5-HT was completely inhibited by calphostin C
(Fig. 8); and (8) the exogenous TGF-b-induced increase in
type IV collagen secretion (Fig. 5B) was not inhibited by
calphostin C (data not shown).
The 5-HT2A subreceptor type is present in high concen-
trations in the brain, platelets, vascular smooth muscle cells
and glomerular mesangial cells [3, 6, 20–23]. Ketanserin is
a well known 5-HT2A receptor antagonist [3, 24]. Sarpogre-
late hydrochloride is also a selective 5-HT2A receptor
antagonist that inhibits 5-HT-induced platelet aggregation
[25] and constriction of vascular smooth muscle cells [25].
In the present study, the 5-HT-induced increase in type IV
collagen secretion by human mesangial cells was com-
pletely suppressed by these 5-HT2A receptor antagonists
but not by the 5-HT3 receptor antagonist, ondansetron
(Fig. 1C) [26], suggesting that the effect of 5-HT was, at
least in part, mediated through 5-HT2A subreceptor type
present on human mesangial cells.
Our results also showed that calphostin C inhibited the
stimulatory effect of 5-HT on the secretion of type IV
collagen (Fig. 6B), while the activity of membrane PKC was
increased by 5-HT (Fig. 6A). Moreover, phorbol ester, a
well known PKC activator, increased the production of type
IV collagen (Fig. 7A). These results strongly suggest that
the effect of 5-HT on type IV collagen secretion is medi-
ated by activation of PKC in mesangial cells. PKC is
involved in agonist-induced cellular responses in various
cell types [27–29]. The enzyme is activated by high concen-
trations of diacylglycerol (DAG) and calcium in the cell
membrane, which are derived from agonist-induced hydro-
lysis of inositol phospholipid [27]. In cultured rat glomer-
ular mesangial cells, 5-HT stimulates the proliferation of
these cells and prostaglandin synthesis by the same cells
[16, 30], which are mediated by stimulation of phospho-
lipase C [16, 30]. This pathway of cellular signals induces a
transient rise in cytosolic calcium followed by activation of
PKC [16]. Thus, it is possible that 5-HT-enhanced produc-
tion of type IV collagen by human mesangial cells is
mediated by activation of phospholipase C, and subse-
quently by a rise in DAG and calcium, and then further by
activation of PKC. Recently, Koya et al reported that PKC
beta was activated in the glomeruli of diabetic rats [31].
Moreover, an oral PKC beta inhibitor ameliorated renal
Fig. 7. Effect of phorbol ester on production
of type IV collagen and TGF-b activity. (A)
Human mesangial cells (5 3 104 cells/well)
were incubated with or without 10 nmol/liter
of phorbol 12-myristate 13-acetate (TPA).
After 24 hours incubation, the concentration
of type IV collagen in the medium was
determined. (B) Human mesangial cells (5 3
104 cells/well) were incubated with 10 nmol/
liter of TPA. After 24 hours of incubation,
total (upper panel) and active (lower panel)
TGF-b bioactivities in the medium were
determined. Data represent the mean 6 SD of
three separate experiments.
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dysfunction of diabetic rats [32]. These studies suggested
that PKC beta might play an important role in the devel-
opment of diabetic nephropathy. However, the PKC family
consists of at least 11 different subspecies of serine/threo-
nine protein kinases [33], such as conventional PKC (a, b1,
b2 and g) and novel PKC (d, e, u and h). Recent studies
have also reported the presence of atypical subspecies of
PKC [33]. Therefore, further studies are necessary to
determine the exact PKC isozyme(s) involved in 5-HT-
enhanced production of type IV collagen by human mes-
angial cells.
5-HT enhanced the production of type IV collagen from
mesangial cells (Fig. 1 A, B) and increased the activity of
active TGF-b (Fig. 4). Moreover, an anti-TGF-b antibody
induced a complete suppression of type IV collagen pro-
duction (Fig. 5A). Furthermore, exogenous active TGF-b
enhanced the type IV collagen production (Fig. 5B). These
results suggest the possible involvement of TGF-b in
5-HT-enhanced production of type IV collagen by mesan-
gial cells. Does the effect of 5-HT on the activity of active
TGF-b represent a direct effect or indirect effect through
activation of PKC? Our results showed that calphostin C
inhibited the effect of 5-HT on collagen secretion (Fig. 6B),
suppressed the effects of 5-HT on TGF-b (Fig. 8), but did
not affect exogenous active TGF-b-induced type IV colla-
gen production (data not shown). Moreover, the time
course studies demonstrated that PKC activity showed
peak activity at 10 minutes (Fig. 6A), TGF-b activity
become significant at 12 hours (Fig. 4B), and collagen
production become significant at 24 hours following the
addition of 5-HT (Fig. 1B). These results suggest that the
effect of 5-HT on TGF-b are probably mediated by activa-
tion of PKC. This conclusion is further supported by results
of previous studies from other laboratories. For example,
Akhurst, Fee and Balmain reported that phorbol esters
stimulated the expression of TGF-b mRNA in mouse
epidermal cells [34]. Moreover, angiotensin II stimulated
the induction of TGF-b mRNA via PKC activation in rat
smooth muscle cells [35]. Furthermore, phorbol esters
induced both PKC activation and TGF-b mRNA in rat
mesangial cells [36]. In mesangial cells, several activators of
PKC have been shown to increase TGF-b mRNA and
bioactivity. These activators include high concentrations of
glucose in mice [37], angiotensin II in rats [38], thrombox-
ane in rats [39], and low density lipoproteins in rats [40], all
of which also increase mesangial cell matrix protein syn-
thesis by mesangial cells.
TGF-b is usually secreted as a biologically inactive form,
latent TGF-b [41]. There are three components of the
latent TGF-b complex: (1) active TGF-b, (2) TGF-b
latency-associated peptide (LAP), and (3) latent TGF-b
binding protein (LTAP) [41]. Since TGF-b is secreted in a
latent form, the dissociation of active TGF-b from the
latent complex is essential for the expression of its biolog-
ical activities post secretion. Latent TGF-b is activated by
proteolysis of the latent complex with plasmin and cathep-
sin D, or by alteration of carbohydrate structures within
LAP. Plasmin cleaves LAP and releases active TGF-b from
latent TGF-b. Tissue-type plasminogen activator (tPA)
converts plasminogen to the proteolytic active plasmin.
Activation of PKC has been shown to induce tPA in HeLa,
HepG2, and Bowes melanoma cells [42]. In fact, human
mesangial cells also secrete tPA [43]. Accordingly, it is
possible that 5-HT-stimulated PKC activation increases
tPA activity, thereby enhancing the activation of latent
TGF-b via an increased level of plasmin.
The signal pathway downstream TGF-b activation to the
Fig. 8. Inhibitory effect of calphostin C on 5-HT-enhanced bioactivities
of total and active TGF-b in human mesangial cells. Human mesangial
cells (5 3 104 cells/well) were incubated with (F) or without (f) 1026
mol/liter of 5-HT in the absence or presence of the indicated concentra-
tions of calphostin C. After 24 hours of incubation, total (upper panel) and
active (lower panel) TGF-b bioactivities in the medium were determined.
Data represent the mean 6 SD of three separate experiments. *P , 0.05,
compared with cells incubated with 1026 mol/liter of 5-HT without
calphostin C.
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secretion of type IV collagen in human mesangial cells
remains unknown. However, previous studies using cul-
tured mouse or rat mesangial cells showed that exogenous
TGF-b increases the production of collagen, fibronectin
and proteoglycan on a protein level [11, 44]. TGF-b also
increases mRNA expression of types I and IV collagen in
rat mesangial cells [12]. Moreover, TGF-b is reported to
promote the deposition of extracellular matrix by stimulat-
ing the synthesis of matrix proteins, increase the activity of
tissue inhibitor of matrix-degrading metalloproteinases,
and/or inhibit the expression of stromelysin, which are
enzymes involved in the metabolism of extracellular matrix
[45, 46].
In the present study, 5-HT-enhanced production of type
IV collagen was observed at concentrations from 1027
mol/liter (Fig. 1A). Interestingly, the concentrations of
plasma 5-HT in diabetic patients ranged from 1028 to 1027
mol/liter [4, 5]. Although the exact concentration and
sources of 5-HT in mesangial lesions in diabetic patients
are still unknown, it is possible that the high plasma
concentrations of 5-HT in diabetic patients may enhance
the production of type IV collagen by glomerular mesangial
cells, thereby enhancing the expansion of mesangial lesions.
Further studies are needed in order to elucidate this issue.
In conclusion, the present in vitro experiments demon-
strated that 5-HT enhanced the production of type IV
collagen by human mesangial cells, which was mediated by
activation of PKC and subsequent increase in the activity of
active TGF-b.
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APPENDIX
Abbreviations used in this article are: 2B9, anti-phosphorylated serine
antibody; CCL-64, Mvl Lu mink lung epithelial cells; DMSO, dimethyl
sulfoxide; FCS, fetal calf serum; HBSS, Hank’s balanced salt solution;
5-HT, 5-hydroxytryptamine; LAP, latency associated protein; LTAP,
latent transforming growth factor-b binding protein; PBS, phosphate
buffered saline; PKC, protein kinase C; TGF-b, transforming growth
factor-b; tPA, tissue-type plasminogen activator.
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